about
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in ChinaAddressing phenoconversion: the Achilles' heel of personalized medicine.Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell linesThe importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.Pharmacogenomics and bioinformatics: PharmGKB.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
KCNH2 pharmacogenomics summary.
@en
KCNH2 pharmacogenomics summary.
@nl
type
label
KCNH2 pharmacogenomics summary.
@en
KCNH2 pharmacogenomics summary.
@nl
prefLabel
KCNH2 pharmacogenomics summary.
@en
KCNH2 pharmacogenomics summary.
@nl
P2093
P2860
P1476
KCNH2 pharmacogenomics summary.
@en
P2093
Caroline F Thorn
Connie Oshiro
Dan M Roden
Teri E Klein
P2860
P304
P356
10.1097/FPC.0B013E3283349E9C
P50
P577
2010-12-01T00:00:00Z